JIANGSU ASCENTAGE BIOMED DEV INC has a total of 14 patent applications. It increased the IP activity by 700.0%. Its first patent ever was published in 2014. It filed its patents most often in China, EPO (European Patent Office) and Republic of Korea. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and environmental technology are IMMUPHARMA FRANCE SA, INGENIUM PHARMACEUTICALS GMBH and ASHWELL MARK A.
# | Country | Total Patents | |
---|---|---|---|
#1 | China | 3 | |
#2 | EPO (European Patent Office) | 2 | |
#3 | Republic of Korea | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 | |
#6 | Hong Kong | 1 | |
#7 | Singapore | 1 | |
#8 | Taiwan | 1 | |
#9 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Heterocyclic compounds | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Yang Dajun | 13 |
#2 | Zhai Yifan | 8 |
#3 | Zhang Xiaoyong | 7 |
#4 | Hou Jinlin | 7 |
#5 | Zhou Yunlong | 5 |
#6 | Bai Longchuan | 5 |
#7 | Wang Shaomeng | 5 |
#8 | Liu Liu | 5 |
#9 | Mceachern Donna | 5 |
#10 | Jing Yu | 5 |
Publication | Filing date | Title |
---|---|---|
HK1252670A1 | Double-diazabicyclo compounds for the treatment and/or prevention of hepatitis virus-related diseases or disorders | |
CN107987083A | For treating and/or preventing double diazabicyclo compounds of relevant with hepatitis viruse disease or illness |